A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Recruiting · 40 sites across 15 states
Always free
Study care at no cost to you
For your time and travel
Many studies pay you back
Most need no insurance or papers
Legal status usually isn't required; we'll tell you each study's requirements
Interpreters available
Ask for your language
Your choice
Voluntary — you can stop anytime
What is this study?
The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.
It is , overseen by an independent and licensed medical staff.
Read the full clinical description
The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.
Who this study is looking for
In plain language, from the study's own rules. The study team confirms the full details with you — this isn't a final yes or no.
✅ You may be able to join if…
- •Adults ages 18 to 75 who can sign consent and follow study visits
- •Have a diagnosis of presumed MASH based on recent biopsy OR FibroScan and metabolic risk factors
- •Have evidence of liver fat on FibroScan and MRI-PDFF at screening
- •BMI in the required range (non-Asian: >25 to <50; Asian: ≥23 to <50)
- •Have elevated ALT and stable liver enzyme levels during screening, and meet kidney and other safety requirements
🚫 You may not be able to join if…
- •People with cirrhosis (based on biopsy and/or imaging and/or signs of portal hypertension)
- •People with liver diseases other than MASLD/MASH (including alcoholic liver disease, autoimmune hepatitis, cholestatic disease, genetic liver diseases, or drug-induced liver injury)
- •People with very high liver enzymes at screening (ALT/AST >5×ULN or ALP >2×ULN)
- •People with clinically significant thyroid or adrenal problems (including uncontrolled hypothyroidism, hyperthyroidism, or adrenal disorders)
- •People who are pregnant or breastfeeding (or have MRI contraindications or other safety concerns)
Are you a good fit?
Simplified highlights. The study team always confirms the full details with you.
- ✓Adults ages 18 to 75 who can consent and follow study visits
- ✓Presumed MASH confirmed by specific liver test results (biopsy or FibroScan plus MRI-PDFF/LSM)
- ✓BMI in the study range (with different cutoffs for Asian vs non-Asian)
- ✓Elevated liver enzymes (ALT at least 60 U/L) with stable liver tests during screening
- ✓Kidney function with eGFR at least 60
- ✓Not pregnant/breastfeeding and no major safety issues like cirrhosis or certain recent heart events
- !Some conditions may not be a fit: Type 2 diabetes, Heart / cardiovascular disease, High blood pressure
- !Not for people who are pregnant or breastfeeding
- !May require a break from current GLP-1 medications
How this study is designed
The real details, in plain words. Tap the underlined words to learn what they mean.
- •Some participants receive a . The study team tells you your chances of getting the active treatment before you decide.
- •You'd be placed into a group by chance, like a coin flip — this keeps the study fair.
- •This study is , so results can't be swayed by expectations. Your medical team always knows what you're getting.
- •There are 6 groups in this study.
What to expect, step by step
· This study lasts about 12 weeks (~3 months)- 1
Usually a few weeks
The study team checks whether the study is a good fit for you, with a visit and sometimes lab tests. You can ask any questions before deciding.
- 2
Treatment
About 12 weeksIf you join and choose to continue, you receive the study treatment and are watched closely by medical staff.
- 3
Follow-up
After treatment, the team checks on your health and confirms the visit schedule with you. You can leave the study at any point.
What's being tested
- Drug: Placebo
- Drug: ECC4703
- Drug: ECC0509
- Drug: ECC4703
Has this treatment been tested before?
Yes. This treatment has already been through earlier human studies for safety before reaching this stage.
Who's running this study?
Sponsor
Eccogene
Overseen by Eccogene Clinical Trials
Every study is also reviewed by an independent that protects participants.
What you need to know before you apply
What is this study testing?+
The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.
Is it safe? Who makes sure of that?+
This is a mid-stage study (Phase 2), looking at safety and whether the treatment works. Every study is reviewed and monitored by an independent ethics board (called an IRB) whose job is to protect participants, and care is overseen by licensed medical staff. You'll be told the known risks before you agree to anything, and you can stop at any time.
Will I get a placebo instead of the real treatment?+
Some studies compare a treatment against a placebo (an inactive version), and some don't. If this one does, the study team will explain your chances of receiving the active treatment before you decide. Nothing is hidden from you.
I take a GLP-1 medication (like Ozempic or Wegovy). Can I still join?+
Maybe. This study may ask you to pause certain weight or diabetes medications for a period of time (a 'washout') before joining, or it may be looking for people not currently on them. The coordinator will review your medications with you — don't stop any medication on your own.
Does it cost anything? Will I be paid?+
The study treatment and study-related visits are provided at no cost to you. Some studies also pay for your time; the coordinator can tell you if this one does. You should never be asked to pay to take part.
Do I need insurance? Will anyone ask about my immigration status?+
No. You do not need health insurance to take part in a research study, and you will not be asked about your immigration status to join. Taking part is about whether you're a medical fit for the study.
What if English isn't my first language?+
You have the right to understand everything before you agree. Study sites can often provide materials or an interpreter in your language — you can ask the coordinator for one.
Is my information private?+
Yes. Your health information is only shared with the study sites you choose to be contacted by, and only to help match and enroll you. It is never sold, and you can ask us to delete it at any time.
Some requirements (like specific lab values or timing) are confirmed directly by the study team, not by us.
Source: ClinicalTrials.gov · NCT07288138 · Locations: Arizona · Arkansas · California · Florida · Georgia · Indiana · Louisiana · Maryland · Missouri · Nevada · New Jersey · North Carolina · Ohio · South Carolina · Texas